Shaokai Zhang

Dr. Shaokai Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
XGXiaoli Guo
Xiaoli Guo
LWLin Wang
Lin Wang
XWXiaoyang Wang
Xiaoyang Wang
DLDongbei Li
Dongbei Li
HWHong Wang
Hong Wang
SZShaokai Zhang
Shaokai Zhang

20 April 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HLHongwei Liu
Hongwei Liu
HXHuifang Xu
Huifang Xu
YLYin Liu
Yin Liu
YZYuqian Zhao
Yuqian Zhao
XZXi Zhang
Xi Zhang
YQYoulin Qiao
Youlin Qiao
Background: The incidence of early-onset colorectal cancer (EOCRC, diagnosed in patients under the age of 50 years) has been increasing around the world. Here, we aimed to systematically identify distinctive features of EOCRC. Methods: From 2020 to 2021, we conducted a nationwide survey in 19 hospitals, collecting data on advanced CRC patients’ demographics, clinical features, disease knowledge, medical experiences, expenditures, and health-related quality of life (HRQOL). We compared these features between EOCRC and late-onset colorectal cancer (LOCRC, ≥ 50 years old) groups and analyzed the association between EOCRC and HRQOL using multivariate linear regression. Findings: In total, 991 patients with EOCRC and 3581 patients with LOCRC were included. Compared to the LOCRC group, the EOCRC group had higher levels of education, were more informed about the risk factors for CRC, were more likely to have widespread metastases throughout the body, were more inclined to undergo gene testing, and were more likely to opt for targeted therapy, radiotherapy, and chemotherapy. However, HRQOL in the EOCRC group was similar to that of the LOCRC group, and no significant association was observed between EOCRC and HRQOL (beta: -0.753, P value: 0.307). Interpretation: In Chinese patients, EOCRC patients had more aggressive features. Despite undergoing more intensified treatments and gene testing, they had similar HRQOL compared with LOCRC. These findings advocate for a more tailored approach to treatment, especially for young CRC patients with advanced TNM stages and metastasis.

15 March 2025 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
HLHongwei Liu
Hongwei Liu
YLYin Liu
Yin Liu
YZYanyan Zhao
Yanyan Zhao
YMYingqi Ma
Yingqi Ma
QCQiong Chen
Qiong Chen
BHBinbin Han
Binbin Han
This review examines global human genetic resources management, focusing on genetic data policies and repositories in high- and middle-low-income countries. A comprehensive search strategy was employed across multiple databases, including official government websites and Google, to gather relevant literature on human genetic resources management policies and genetic resource databases. Documents were screened for relevance, focusing on high-income countries (United States, United Kingdom, Japan) and middle-low-income countries (China, India, Kenya). Data were extracted, coded, and analyzed to identify common themes and differences in genetic resource management practices. High-income countries benefit from robust legal frameworks and advanced technological infrastructures. The United States enforces the Health Insurance Portability and Accountability Act and the Genetic Information Nondiscrimination Act to protect privacy and facilitate data sharing, while Japan relies on the Act on the Protection of Personal Information and ethical guidelines. Additionally, high-income countries host a variety of genetic databases and biobanks that support scientific research. In contrast, middle-low-income countries like China, India, and Kenya are still developing their frameworks. China has regulations such as the Biosecurity Law and the Regulations on the Management of Human Genetic Resources, but still requires more unified standards. India’s policies focus on genetic research and data protection through the Biological Diversity Act, while Kenya seeks to improve data management through the 2019 Data Protection Act. Significant disparities exist in human genetic resources management between high-income and middle-low-income countries. High-income countries have robust systems balancing privacy protection with research facilitation, supported by comprehensive and large-scale databases for scientific research. Middle-low-income countries need to enhance legal frameworks and build population-specific databases. Promoting equitable data sharing and adopting best practices from high-income countries are essential for advancing global scientific discovery and ensuring fair management of genetic resources.

8 February 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
XNXiaoge Niu
Xiaoge Niu
HLHongwei Liu
Hongwei Liu
YWYanxi Wang
Yanxi Wang
YLYanfang Lu
Yanfang Lu
XJXiaojing Jiao
Xiaojing Jiao
FSFengmin Shao
Fengmin Shao
Associations between sleep duration and incident diabetic microvascular complications remain uncertain. The potential biological pathways underlying the association are unclear. This prospective cohort study included 24,081 participants with type 2 diabetes from the UK Biobank. Habitual sleep duration was obtained via a baseline questionnaire. Associations of sleep duration with microvascular complications were analyzed using Cox regression models. The association of sleep duration with composite microvascular complications followed U-shaped patterns. Compared with sleeping for 7 hrs/day, the hazard ratios (95 % confidence intervals) of ≤ 5 and ≥ 10 hrs/day were 1.21 (1.09, 1.35) and 1.24 (1.09, 1.42) for the composite outcome, 1.20 (1.04, 1.38) and 1.30 (1.09, 1.54) for diabetic kidney disease, 1.61 (1.30, 2.00) and 1.35 (1.01, 1.79) for diabetic neuropathy, and 1.10 (0.93, 1.30) and 1.17 (0.95, 1.44) for diabetic retinopathy. Body mass index, gamma-glutamyl transferase, C-reactive protein, alkaline phosphatase, total cholesterol, and low-density lipoprotein cholesterol collectively explained 20.34 % of the association between sleep duration and composite microvascular complications. Our study demonstrated that both short and long sleep durations were independently associated with increased risk of diabetic microvascular complications. The associations were partially mediated by metabolic biomarkers related to obesity, systemic inflammation, liver function, and lipid profile.

23 August 2024 in Academic Radiology
Verified
Journal Article
Closed access
HXHui-Fang Xu
Hui-Fang Xu
HWHong Wang
Hong Wang
YLYin Liu
Yin Liu
XWXiao-Yang Wang
Xiao-Yang Wang
XGXiao-Li Guo
Xiao-Li Guo
SZShaokai Zhang
Shaokai Zhang

19 December 2024 in Journal of the National Cancer Center
Verified
Journal Article
Open access
QCQiong Chen
Qiong Chen
SLShuzheng Liu
Shuzheng Liu
YLYin Liu
Yin Liu
HLHongwei Liu
Hongwei Liu
HWHong Wang
Hong Wang
SZShaokai Zhang
Shaokai Zhang
To understand the current status and changing trends in the lifetime risk of residents in Henan Province, China to develop and die from cancer. Lifetime risk was estimated using the Adjusted for Multiple Primaries (AMP) method, incorporating cancer incidence, mortality, and all-cause mortality data from 55 cancer registries in Henan Province, China. Estimates were calculated overall and stratified by gender and area. The annual percent change (APC) in lifetime risk from 2010 to 2020, stratified by gender and cancer site, was estimated using a log-linear model. In 2020, the lifetime risk of developing and dying from cancer was 30.19 % (95 % CI: 29.63 %–30.76 %) and 23.62 % (95 % CI: 23.28 %–23.95 %), respectively. These estimates were higher in men, with values of 31.22 % (95 % CI: 30.59 %–31.85 %) for developing cancer and 26.73 % (95 % CI: 26.29 %–27.16 %) for dying from cancer, compared with women, who had values of 29.02 % (95 % CI: 28.12 %–29.91 %) and 20.08 % (95 % CI: 19.51 %–20.64 %), respectively. There were also geographical differences, with higher estimates in urban areas compared with rural areas. Residents had the highest lifetime risk of developing lung cancer, with a rate of 6.94 %, followed by breast cancer (4.14 %), stomach cancer (3.95 %), esophageal cancer (3.75 %), and liver cancer (2.86 %). Similarly, the highest lifetime risk of dying from cancer was observed for the following sites: lung (5.99 %), stomach (3.60 %), esophagus (3.39 %), liver (2.78 %), and colorectum (1.55 %). Overall, the lifetime risk of developing cancer increased, with an APC of 0.75 % (P < 0.05). Varying trends were observed across different cancer sites. There were gradual decreases in nasopharynx, esophagus, stomach, and liver cancers. Conversely, increasing trends were noted for most other sites, with the highest APCs observed in thyroid, prostate, lymphoma, kidney, and gallbladder cancers. The lifetime risks of developing and dying from cancer were 30.19 % and 23.62 %, respectively. Variations in cancer risk across different regions, genders, specific cancer sites, and over calendar years provide important information for cancer prevention and policy making in the population.